Page last updated: 2024-10-27

gabapentin and Drug Refractory Epilepsy

gabapentin has been researched along with Drug Refractory Epilepsy in 8 studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Research Excerpts

ExcerptRelevanceReference
"Gabapentin as monotherapy probably controlled seizures no better and no worse than comparator AEDs (lamotrigine, carbamazepine, oxcarbazepine, and topiramate)."9.41Gabapentin monotherapy for epilepsy: A review. ( Abakumova, T; Hoyle, CHV; Ziganshina, LE, 2023)
"To evaluate the comparative safety and adjunctive efficacy of pregabalin and gabapentin in reducing seizure frequency in patients with partial-onset seizures based on prestudy modeling showing superior efficacy for pregabalin."9.22Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes. ( Almas, M; French, J; Friedman, D; Glue, P; Knapp, L; Pitman, V; Posner, HB; Yardi, N, 2016)
"Cannabidiol and cannabidiol-enriched products have recently attracted much attention as an add-on therapy for epilepsy, especially drug-resistant seizures."7.91Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies. ( Nieoczym, D; Socała, K; Szafarz, M; Wlaź, P; Wyska, E, 2019)
"Gabapentin as monotherapy probably controlled seizures no better and no worse than comparator AEDs (lamotrigine, carbamazepine, oxcarbazepine, and topiramate)."5.41Gabapentin monotherapy for epilepsy: A review. ( Abakumova, T; Hoyle, CHV; Ziganshina, LE, 2023)
"To evaluate the comparative safety and adjunctive efficacy of pregabalin and gabapentin in reducing seizure frequency in patients with partial-onset seizures based on prestudy modeling showing superior efficacy for pregabalin."5.22Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes. ( Almas, M; French, J; Friedman, D; Glue, P; Knapp, L; Pitman, V; Posner, HB; Yardi, N, 2016)
"Cannabidiol and cannabidiol-enriched products have recently attracted much attention as an add-on therapy for epilepsy, especially drug-resistant seizures."3.91Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies. ( Nieoczym, D; Socała, K; Szafarz, M; Wlaź, P; Wyska, E, 2019)
"Gabapentin has efficacy as an add-on treatment in people with drug-resistant focal epilepsy, and seems to be fairly well-tolerated."2.72Gabapentin add-on treatment for drug-resistant focal epilepsy. ( Al-Bachari, S; Hutton, JL; Marson, AG; Panebianco, M, 2021)
"28), indicating a dose-response relationship."2.61Pregabalin add-on for drug-resistant focal epilepsy. ( Bresnahan, R; Hemming, K; Marson, AG; Panebianco, M, 2019)
"Gabapentin has efficacy as an add-on treatment in people with drug-resistant focal epilepsy."2.58Gabapentin add-on treatment for drug-resistant focal epilepsy. ( Al-Bachari, S; Hutton, JL; Marson, AG; Panebianco, M; Weston, J, 2018)
"Oxcarbazepine was used in 82 patients, topiramate in 120 patients, lamotrigine in 73 patients, levetiracetam in 135 patients, pregabalin in 47 patients, tiagabine in 43 patients, gabapentin in 18 patients, lacosamide in 12 patients, and retigabine in 6 patients."1.48Comparative effectiveness of add-on therapy with newer-generation antiepileptic drugs in Bulgarian patients with refractory epilepsy. ( Viteva, E; Zahariev, Z, 2018)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (75.00)24.3611
2020's2 (25.00)2.80

Authors

AuthorsStudies
Ziganshina, LE1
Abakumova, T1
Hoyle, CHV1
Panebianco, M3
Al-Bachari, S2
Hutton, JL2
Marson, AG3
Viteva, E1
Zahariev, Z1
Weston, J1
Bresnahan, R1
Hemming, K1
Socała, K1
Wyska, E1
Szafarz, M1
Nieoczym, D1
Wlaź, P1
Gill, I1
Parrent, AG1
Steven, DA1
French, J1
Glue, P1
Friedman, D1
Almas, M1
Yardi, N1
Knapp, L1
Pitman, V1
Posner, HB1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures.[NCT00537940]Phase 4482 participants (Actual)Interventional2008-02-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percent Change From Baseline in 28-day Seizure Frequency at Week 21.

The seizures were recorded by the participants, by a family member, by a caregiver, or by a legal guardian and documented in a daily seizure diary. Participant's 28-day seizure frequency of all partial seizure was assessed during double blind (TP + MP) phase compared with baseline. Total partial seizure is defined as the total number of (simple partial seizure + complex partial seizure + secondary generalized tonic clonic seizure [SGTC]). (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks

Interventionpercent change (Median)
Pregabalin-58.65
Gabapentin-57.43

Reduction in Proportion of the 28-day SGTC Seizure Rate Over the Total Partial Seizure Rate at Week 21.

SGTC Responder is defined as a participant who shows reduction from Baseline to double-blind phase in proportion of 28-Day SGTC Seizure Rate to 28-Day All Partial Seizure Rate. (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks

Interventionpercentage of responders (Number)
Pregabalin30.8
Gabapentin39.8

Change From Baseline in the 28-day Secondarily Generalized Tonic-clonic (SGTC) Seizure Frequency at Week 21.

Change in SGTC = (Proportion of SGTC/All Partial Seizure rate during at the double-blind phase) - (Proportion of SGTC/All Partial Seizure rate at Baseline). Negative values indicate reduction from baseline. (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks

,
Interventionpercentage of all partial seizure/28days (Mean)
Baseline (n=114, 114)Change from Baseline at Double Blind (n=104, 98)
Gabapentin59.60-2.17
Pregabalin56.531.59

Hospital Anxiety and Depression Scale (HADS) Score.

HADS: participant rated questionnaire with 2 subscales. Hospital Anxiety and Depression Scale - anxiety (HADS-A) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); Hospital Anxiety and Depression Scale - depression (HADS-D) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms. (NCT00537940)
Timeframe: Baseline, Week 21

,
InterventionUnits on a scale (Least Squares Mean)
Baseline HADS-A (n=238, 240)HADS- A Change at Week 21/ET (n=212, 210)Baseline HADS-D (n=238, 240)HADS-D Change at Week 21/ET (n=212, 210)
Gabapentin7.60-0.835.65-0.42
Pregabalin7.82-0.925.94-0.59

Medical Outcomes Study Sleep Scale (MOS-SS) Score.

Participant-rated 12-item questionnaire to assess constructs of sleep over past week; 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity (range:0-24), optimal sleep (yes/no), and 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except adequacy, optimal sleep and quantity, higher scores=more impairment. Scores transformed (actual raw score [RS] minus lowest possible score divided by possible RS range*100); total score range:0-100; higher score=more intensity of attribute. (NCT00537940)
Timeframe: Baseline, Week 21

,
InterventionUnits on a scale (Least Squares Mean)
Baseline: Sleep Disturbance (n=238, 240)Baseline: Snoring (n=238, 240)Baseline: Awaken Short of Breath (n=238, 240)Baseline: Quantity of Sleep (n=238, 240)Baseline: Adequacy of Sleep (n=238, 240)Baseline: Somnolence (n=238, 240)Baseline: Sleep Problem Index (9) (n=238, 240)Week 21: Sleep Disturbance (n=212, 210)Week 21: Snoring (n=212, 210)Week 21: Awaken Short of Breath (n=212, 210)Week 21: Quantity of Sleep (n=212, 210)Week 21: Adequacy of Sleep (n=212, 210)Week 21: Somnolence (n=212, 210)Week 21: Sleep Problem Index (9) (n=212, 210)
Gabapentin26.4328.0919.617.5963.6729.3128.1525.3126.1218.208.7764.5329.9827.54
Pregabalin29.6829.2823.647.5661.3032.2931.6024.9928.0716.268.7963.8732.0427.88

Percentage of Participants With 50% Reduction From Baseline in 28-day Seizure Rate at Week 21.

Participants who had at least 50% reduction in seizure frequency from Baseline to double-blind treatment (TP + MP) were considered as 50% responders. If percent change from baseline <= -50 then responder rate = 1 (yes) otherwise responder rate = 0 (no). (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks

,
InterventionPercentage of participants (Number)
All Partial Seizure (n=238, 240)Simple Partial (n=87, 88)Complex Partial (n=161, 158)SGTC (n=112, 114)
Gabapentin58.353.455.160.5
Pregabalin56.355.256.550.9

Percentage of Participants With 75% Reduction From Baseline in 28-day Seizure Rate at Week 21.

Participants who had at least 75% reduction in seizure frequency from Baseline to double-blind treatment (TP + MP) were considered as 75% responders. If percent change from baseline <= -75 then 75% responder rate = 1 (yes) otherwise responder rate = 0 (no). Total partial seizure is defined as the total number of (simple partial seizure + complex partial seizure + SGTC). (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks

,
InterventionPercentage of participants (Number)
All Partial Seizure (n=238, 240)Simple Partial (n=87, 88)Complex Partial (n=161, 158)SGTC (n=112, 114)
Gabapentin34.233.036.143.9
Pregabalin33.636.837.338.4

Percentage of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) Score.

MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Percentage of participants with optimal sleep are reported. (NCT00537940)
Timeframe: Baseline, Week 21

,
Interventionpercentage of participants (Number)
Baseline (n=238, 240)Week 21 (n=212, 210)
Gabapentin58.858.6
Pregabalin49.251.4

Percentage of Participants Without Seizures.

Seizure free for 28 days was defined as participants who have not experienced any seizure (simple partial, complex partial and SGTC) for at least 28 consecutive days from their last seizure until the end of the MP. Same participant could be seizure free for a specific type of seizure but not necessarily for the other types of seizure. (NCT00537940)
Timeframe: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks

,
Interventionpercentage of participants (Number)
All Partial Seizure (n=189, 182)Simple Partial (n=74, 66)Complex Partial (n=126, 123)SGTC (n=95, 91)
Gabapentin34.136.440.742.9
Pregabalin30.729.737.346.3

Reviews

4 reviews available for gabapentin and Drug Refractory Epilepsy

ArticleYear
Gabapentin monotherapy for epilepsy: A review.
    The International journal of risk & safety in medicine, 2023, Volume: 34, Issue:3

    Topics: Anticonvulsants; Carbamazepine; Drug Resistant Epilepsy; Epilepsies, Partial; Epilepsy; Gabapentin;

2023
Gabapentin add-on treatment for drug-resistant focal epilepsy.
    The Cochrane database of systematic reviews, 2021, 01-12, Volume: 1

    Topics: Adult; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Resistant Epilepsy; Drug Therapy, C

2021
Gabapentin add-on treatment for drug-resistant focal epilepsy.
    The Cochrane database of systematic reviews, 2018, 10-24, Volume: 10

    Topics: Adult; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Resistant Epilepsy; Drug Therapy, C

2018
Pregabalin add-on for drug-resistant focal epilepsy.
    The Cochrane database of systematic reviews, 2019, 07-09, Volume: 7

    Topics: Anticonvulsants; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, Partial; Gabapentin

2019

Trials

1 trial available for gabapentin and Drug Refractory Epilepsy

ArticleYear
Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes.
    Neurology, 2016, Sep-20, Volume: 87, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Ac

2016

Other Studies

3 other studies available for gabapentin and Drug Refractory Epilepsy

ArticleYear
Comparative effectiveness of add-on therapy with newer-generation antiepileptic drugs in Bulgarian patients with refractory epilepsy.
    Epilepsy & behavior : E&B, 2018, Volume: 87

    Topics: Adult; Anticonvulsants; Bulgaria; Drug Resistant Epilepsy; Drug Therapy, Combination; Female; Gabape

2018
Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies.
    Neuropharmacology, 2019, 11-01, Volume: 158

    Topics: Animals; Anticonvulsants; Brain; Cannabidiol; Chromatography, High Pressure Liquid; Disease Models,

2019
Trigeminal neuropathic pain as a complication of anterior temporal lobectomy: report of 2 cases.
    Journal of neurosurgery, 2016, Volume: 124, Issue:4

    Topics: Amines; Analgesics; Anterior Temporal Lobectomy; Cyclohexanecarboxylic Acids; Drug Resistant Epileps

2016